Industry Symposia
on the occasion of the
55th EASD Annual Meeting

www.easd-industry.com

Organised by

INTERPLAN
media & service gmbh
<table>
<thead>
<tr>
<th>Industry Symposia</th>
<th>09:00</th>
<th>10:00</th>
<th>11:00</th>
<th>12:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joslin Hall Novo Nordisk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ochoa Hall SANOFI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Servet Hall AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Averroes Hall Novartis Pharma AG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serrano-Rios Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carrasco Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vilanova Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hortega Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Llull Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maimonides Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trueta Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Industry Symposium Schedule

**Monday, 16 September 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>13:00</th>
<th>14:00</th>
<th>15:00</th>
<th>16:00</th>
<th>17:00</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15:00 – 17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Boehringer Ingelheim & Eli Lilly and Company Alliance**

14:30 – 16:30

- **Abbott**
  - 14:30 – 17:00

- **Dexcom**
  - 14:30 – 17:00

- **MSD**
  - 14:30 – 17:00

- **Roche Diabetes Care GmbH**
  - 14:30 – 17:00

- **Bayer AG**
  - 14:30 – 17:00

- **PeerVoice**
  - 16:00 – 17:30

*Status July 2019, details are subject to change.*
## INDUSTRY SYMPOSIA SCHEDULE

### Industry Morning Symposia  
**Wednesday, 18 September 2019**

<table>
<thead>
<tr>
<th>Hall</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinós Hall</td>
<td>ESWI</td>
</tr>
</tbody>
</table>

### Industry Evening Symposia  
**Wednesday, 18 September 2019**

<table>
<thead>
<tr>
<th>Hall</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serrano-Rios Hall</td>
<td>Novartis Pharma AG</td>
</tr>
<tr>
<td>Carrasco Hall</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>Hortega Hall</td>
<td>SANOFI</td>
</tr>
<tr>
<td>Averroes Hall</td>
<td>Mundipharma</td>
</tr>
<tr>
<td>Llull Hall</td>
<td>SERVIER</td>
</tr>
<tr>
<td>Sols Hall</td>
<td>Worldwide Initiative for Diabetes Education</td>
</tr>
</tbody>
</table>

### Industry Mini Symposia  
**Wednesday, 18 September 2019**

<table>
<thead>
<tr>
<th>Hall</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maimonides Hall</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Pinós Hall</td>
<td>Merck KGaA</td>
</tr>
</tbody>
</table>

### Industry Morning Symposia  
**Thursday, 19 September 2019**

<table>
<thead>
<tr>
<th>Hall</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Averroes Hall</td>
<td>L-Nutra Italia S.r.l.</td>
</tr>
</tbody>
</table>

### Industry Evening Symposia  
**Thursday, 19 September 2019**

<table>
<thead>
<tr>
<th>Hall</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carrasco Hall</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>Hortega Hall</td>
<td>Sanofi and Regeneron</td>
</tr>
<tr>
<td>Averroes Hall</td>
<td>MSD</td>
</tr>
<tr>
<td>Llull Hall</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Maimonides Hall</td>
<td>Nemaura Medical</td>
</tr>
</tbody>
</table>

### Industry Mini Symposia  
**Thursday, 19 September 2019**

<table>
<thead>
<tr>
<th>Hall</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinós Hall</td>
<td>Bayer AG</td>
</tr>
</tbody>
</table>
### Morning Sessions

<table>
<thead>
<tr>
<th>Tuesday, 17 September 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 11:00</td>
</tr>
<tr>
<td>Networking Hub</td>
</tr>
</tbody>
</table>

### Lunch Sessions

| 13:00 – 13:30 | 14:00 – 14:30 |
| Networking Hub | MSD  |

### Morning Sessions

<table>
<thead>
<tr>
<th>Wednesday, 18 September 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 11:00</td>
</tr>
<tr>
<td>Networking Hub</td>
</tr>
</tbody>
</table>

### Lunch Sessions

| 13:00 – 13:30 | 14:00 – 14:30 |
| Networking Hub | SANOFI  |

### Morning Session

<table>
<thead>
<tr>
<th>Thursday, 19 September 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 11:00</td>
</tr>
<tr>
<td>Networking Hub</td>
</tr>
</tbody>
</table>

### Lunch Sessions

| 13:00 – 13:30 | 14:00 – 14:30 |
| Networking Hub | Aegerion  |

### Afternoon Session

| 15:00 – 15:30 |
| Networking Hub | Gilead Sciences, Inc.  |

*Status July 2019, details are subject to change.*
Full Day Session

Co-chairs: John Cunningham (UK) and Juris J Meier (Germany)

09:00 – 11:05  ADVANCING INSULIN INNOVATION FOR PEOPLE WITH DIABETES

09:00  Welcome and introduction
John Cunningham (UK) and Juris J Meier (Germany)

09:10 – 10:45  Why should hypoglycaemia be a compromise?
Athena Philis-Tsimikas (USA)
Lena Landstedt-Hallin (Sweden)

Durability of a dual approach
Liana Billings (USA)

Intensified insulin management around mealtimes
Stephen C Bain (UK)

Practical steps for insulin intensification
All

Keynote: Glucose management beyond HbA$_1$c
Richard Bergenstal (USA)

10:45 – 11:05  Coffee break

11:05 – 13:15  OPTIMISING THE USE OF GLP-1RAS IN PEOPLE WITH TYPE 2 DIABETES

11:05  Welcome back
John Cunningham (UK) and Juris J Meier (Germany)

11:10 – 12:25  Treatment intensification with semaglutide OW
Rory McCrimmon (UK)

Real-world evidence in type 2 diabetes care
Marc Evans (UK)

Clinical implications of evidence from cardiovascular outcomes trials
Subodh Verma (Canada)

Clinical aspects of use of GLP-1RAs
All
MOVING BEYOND THE STANDARD: TAILORING CARE IN DIABETES AND OBESITY

Full Day Session

12:25 – 13:15  *Lunch*

13:15 – 14:30  **OPTIMISING THE USE OF GLP-1RAS IN PEOPLE WITH OBESITY**

13:15  Welcome back
John Cunningham (UK) and Juris J Meier (Germany)

13:20 – 14:10  **The role of IBT in weight management**
Thomas Wadden (USA)

*Weight management in people with type 2 diabetes on insulin*
Ofri Mosenzon (Israel)

*Integrating weight management into type 2 diabetes care*
All

14:10 – 14:30  *Coffee break*

14:30 – 15:35  **FUTURE PERSPECTIVES FOR TYPE 2 DIABETES CARE**

14:30  Welcome back
John Cunningham (UK) and Juris J Meier (Germany)

14:35 – 15:30  **Oral GLP-1RAs – a new approach to diabetes treatment***
Melanie Davies (UK)

*Evaluating clinical relevance of an oral GLP-1RA in different populations*
Vanita Aroda (USA)

*Patient-centered decision making*
All

15:30 – 15:35  *Close of the day*
John Cunningham (UK) and Juris J Meier (Germany)

---

*Not marketed in Spain*

Organised by: Novo Nordisk
DIABETES JOURNEY:
INNOVATIVE SOLUTIONS FOR INDIVIDUAL NEEDS

Full Day Session

Chairs: Jay Skyler, Leigh Perreault

09:00 – 09:10 Welcome and introduction
       Jay Skyler, Leigh Perreault

09:10 – 09:40 Understanding diabetes pathophysiology and the mechanism of diabetic complications
           Mark Cooper

SESSION 1: Selecting insulin options to meet patients’ needs

09:40 – 09:45 Session introduction
           Leigh Perreault

09:45 – 10:05 Updates and advantages of 2nd-generation basal insulin analogs
           Pratik Choudhary

10:05 – 10:25 Renal function and glucose control with basal insulins
           Alice Cheng

10:25 – 10:45 Real-life relevance of 2nd-generation basal insulin analogs in high-risk patients
           Kamlesh Khunti

10:45 – 10:55 Audience Q&A

SESSION 2: Beyond HbA1c: Individualizing treatment with adjunct therapy and technology

10:55 – 11:00 Session introduction
           Jay Skyler

11:00 – 11:25 Driving innovation in T1D with dual SGLT-1 and -2 inhibition
           Jeremy Pettus

11:25 – 11:50 Beyond HbA1c: Measuring the impact of adjunct therapy on the new metrics of control
           Thomas Danne

11:50 – 12:00 Audience Q&A

12:00 – 13:00 Lunch
DIABETES JOURNEY:
INNOVATIVE SOLUTIONS FOR INDIVIDUAL NEEDS

Full Day Session

SESSION 3:  Personalizing outcomes: Optimizing treatment options across the patient spectrum
13:00 – 13:10  Session introduction
             Jay Skyler
13:10 – 13:30  Personalizing injectable treatments in T2D
             Leigh Perreault
13:30 – 13:50  Emerging strategies to advance GLP-1 receptor agonist therapies in T2D
             Julio Rosenstock
13:50 – 14:10  Dyslipidemia and diabetes: Personalizing treatment to address CV risk
             Jose-Luis Zamorano
14:10 – 14:30  Targeting the right patient: Improving outcomes with PCSK9 inhibitors
             Helen Colhoun
14:30 – 14:40  Audience Q&A

SESSION 4:  Looking at the big picture: Advances in patient care
14:40 – 14:45  Session introduction
              Leigh Perreault
14:45 – 15:10  Beta-cell replacement therapy: Hope for the future
              Jay Skyler
15:10 – 15:20  Diabetes. Your Type.
15:20 – 15:30  Close and wrap-up
              Jay Skyler, Leigh Perreault

Organised by:  SANOFI
CARDIO-RENAL-METABOLIC REVOLUTION: ARE YOU READY?

Full Day Session

Chair: Eduard Montanya (Spain) and Jiten Vora (UK)

09:00 – 09:30 Cardiovascular-renal-metabolic management of patients with T2D: The journey so far
John Buse (USA)
Francesco Giorgino (Italy)

09:30 – 09:40 Welcome and introductions
Eduard Montanya (Spain)
Jiten Vora (UK)

Revolution in the management of cardio-renal-metabolic risk across the continuum: Following a T2D patient, prior to an acute coronary syndrome (ACS) event – Introduced by Naresh Kanumilli

09:40 – 10:40 PART 1: Cardio-renal-metabolic general practitioner consult: Preventing complications in a recently diagnosed patient with T2D
Subodh Verma (Canada)
Mark Petrie (UK)
Filip Knop (Denmark)
Roopa Mehta (Mexico)
David Cherney (Canada)

10:40 – 11:15 PART 2: Five years on: Maintaining glycemic control and maximizing cardio-renal risk reduction
Subodh Verma (Canada)
Mark Petrie (UK)
Filip Knop (Denmark)
Roopa Mehta (Mexico)
David Cherney (Canada)

11:15 – 11:30 Coffee Break

11:30 – 12:15 PART 3: Moving along the risk continuum: Managing multiple vascular complications
Mark Petrie (UK)
Francesco Giorgino (Italy)
David Cherney (Canada)

12:15 – 13:00 Lunch
CARDIO-RENAL-METABOLIC REVOLUTION: ARE YOU READY?

Full Day Session

Revolution in the management of cardio-renal-metabolic risk across the continuum: Following a T2D patient, post ACS

13:00 – 13:30  PART 4: Reducing the risk of recurrent CV events, post ACS
Subodh Verma (Canada)
Mark Petrie (UK)
Filip Knop (Denmark)
Roopa Mehta (Mexico)
Hiddo L Heerspink (The Netherlands)

13:30 – 14:00  PART 5: Preventing further cardio-renal decline
Subodh Verma (Canada)
Mark Petrie (UK)
Filip Knop (Denmark)
Roopa Mehta (Mexico)
Hiddo L Heerspink (The Netherlands)

14:00 – 14:30  Summary and overview: Optimizing therapy for risk mitigation across the cardio-renal-metabolic continuum
John Buse (USA)
Subodh Verma (Canada)
Mark Petrie (UK)
Hiddo L Heerspink (The Netherlands)

14:30 – 14:55  Cardio-renal-metabolic risk minimization in T2D: The revolution
John Buse (USA)
Francesco Giorgino (Italy)

14:55 – 15:00  Summary and close
Jiten Vora (UK)
Eduard Montanya (Spain)

Organised by: AstraZeneca
THE DEADLY DUO OF HEART FAILURE AND DIABETES:
CRISIS OR HOPE?

Morning Session

10:00 – 10:03  Welcome and Introduction
Martin R. Cowie (Co-Moderator)

10:03 – 10:13  What Makes Heart Failure and Diabetes the Deadly Duo?
Clifford J. Bailey

Needs to Know!
Adriaan A. Voors

10:28 – 10:48  Diabetes and Heart Failure: the Specialists’ Perspective!
Melanie Davies
Adriaan A. Voors

10:48 – 11:03  Panel Discussion: Managing Heart Failure in Patients
With and Without Diabetes
Martin R. Cowie (Co-Moderator)

11:03 – 11:13  Breaking News in Heart Failure: What Should All
Diabetologists Be Aware Of?
Martin R. Cowie

11:13 – 11:28  Panel Discussion and Audience Questions
Melanie Davies (Co-Moderator)

11:28 – 11:30  Concluding Remarks
Melanie Davies (Co-Moderator)

Organised by:  Novartis Pharma AG
BEYOND METFORMIN IN PATIENT-CENTRED TREATMENT OF DIABETES: HOW TO MAKE GUIDELINE-DIRECTED TREATMENT DECISIONS IN EVERYDAY PRACTICE

Afternoon Session

Co-chairs: Bernard Zinman
José Ramón González Juanatey

14:30 Welcome and introduction
· The paradigm of diabetes treatment decisions has changed to reflect patient burden with kidney disease and cardiovascular risk
Bernard Zinman
José Ramón González Juanatey

14:40 Achieving cardiovascular benefits in patients across the spectrum of cardiovascular risk burden
Kausik Ray

15:05 Opportunities to improve outcomes in patients with kidney impairment
Per-Henrik Groop

15:25 The role of DPP-4 inhibitors in today’s T2D management – what have we learned from recent cardiovascular outcomes trials?
Bernard Zinman

15:50 Choose your own topic
Vote to hear one of three presentations:
· Mechanism of action of SGLT2 inhibitors
  Per-Henrik Groop
· Practical management of patients taking SGLT2 inhibitors
  Bernard Zinman
· Exploring the health economic implications of SGLT2 inhibitors
  Kausik Ray

16:05 Applying guidelines in practice: panel discussion on patient-centred care
Panel discussion and audience Q&A
All faculty

16:30 Summary and close
Bernard Zinman and José Ramón González Juanatey

Organised by: Boehringer Ingelheim & Eli Lilly and Company Alliance
Afternoon Session

**14:30 – 14:45** The current landscape of sensor-based Continuous Glucose Monitoring (CGM): The rationale and role for technology-based approaches to optimize the efficacy-safety equation for managing diabetes
Fernando Gomez-Peralta (Spain)

**14:45 – 15:05** Sensor technology-centric devices and innovations for Continuous Glucose Monitoring: Real world studies and applications in type 1 and type 2 diabetes
Emma G. Wilmot (United Kingdom)

**15:05 – 15:25** Translating landmark clinical trials in sensor-based CGM technology to the front lines of type 1 and type 2 diabetes care: Focus on sensor accuracy, device use, and interpretation of data to optimize treatment decisions
Thomas Danne (Germany)

**15:25 – 15:45** Identifying type 1 and type 2 diabetic patients who are appropriate candidates for sensor-based CGM technology: All CGM devices are not created equal
William H. Polonsky (United States)

**15:45 – 16:15** Real world, interactive case management sessions utilizing audience response system: Case studies focused on Identifying Persons with type 1 and type 2 diabetes: Who can benefit from patient-directed, sensor-based CGM
Fernando Gomez-Peralta (Spain)

**16:15 – 16:30** The foundational role of collaborative-physician and patient-assessment of diabetic treatment goals using sensor-based CGM
Fernando Gomez-Peralta (Spain)

Organised by: Abbott
DEXCOM CGM: TECHNOLOGY LEADER DRIVING TOWARD STANDARD OF CARE

Afternoon Session

Glycemic Assessment with CGM Emerging as the New Standard:
Moving from HbA1c to Time in Range
Tadej Battelino (Slovenia)

Accuracy Comparison of Two CGM System and Its Implications to Patient Care
Guido Freckmann (Germany)
Jessica Castle (USA)

International Diabetes Closed-Loop (iDCL) Trial:
Pivotal Trial Data from the Next Generation Hybrid Closed Loop System
Boris Kovatchev (USA)

Dexcom CGM Technology: The G6 Platform and Beyond
Jake Leach (USA)

Organised by: Dexcom
BUILDING THE LATEST SCIENTIFIC AND CLINICAL UNDERSTANDING FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

Afternoon Session

14:30 – 14:35 Chair Welcome and Opening Remarks
Co-Chairs: Steven Kahn (USA)
Daniel Drucker (Canada)

14:35 – 14:50 Recent Advancements in the Alpha Cell and the Beta Cell: Scientific Spotlight
Dan Drucker (Canada)

14:50 – 15:05 Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes
Hertzel Gerstein (Canada)

Juan Frias (USA)

15:25 – 15:45 Clinical Application with Focus on Clinical Inertia – An Interactive Session
Faculty

15:45 – 16:00 Ertugliflozin: A New SGLT2 Inhibitor for Patients with Type 2 Diabetes
Sam Dagogo-Jack (USA)

16:00 – 16:15 Highlighting the Combination of DPP-4 Inhibitors and SGLT2 Inhibitors in the Treatment of Patients with Type 2 Diabetes
Michael Nauck (Germany)

16:15 – 16:35 Clinical Application with Focus on Why and When We Should Take the Next Treatment Steps – An Interactive Session
Faculty

16:35 – 16:55 Envisioning the Future of SGLT2 Inhibitors in the Treatment of Patients with Diabetes and Renal Disease: Views from the Nephrology
Community Speaker: Ofri Mosenzon (Israel)

16:55 – 17:00 Final Comments and Summary
Chairpersons

Organised by: MSD
CONNECTING THE DOTS: HOW ALGORITHMS HELP TO ADVANCE DIABETES THERAPY

Afternoon Session

Chairs: Rosa Corcoy (Spain)  Rolf Hinzmann (Germany)

14:30 – 14:40  Introduction

14:40 – 15:05  Algorithms in medicine: Current use, challenges and the future potential
                Daniel Sonntag (Germany)

15:05 – 15:30  New digital solutions support to seize the benefits of integrated Personalised Diabetes Management
                Ralph Ziegler (Germany)

15:30 – 15:55  How digital solutions can make a difference in daily life with diabetes
                Katarina Braune (Germany)

15:55 – 16:20  Data integration and security: Essential to optimise therapy within an open ecosystem
                Olivier Convard (Spain)

16:20 – 16:45  Latest developments in insulin delivery: What’s new and next?
                Julia Mader (Austria)

16:45 – 17:00  Discussion and closing

Organised by: Roche Diabetes Care GmbH
REDUCING THE RISK OF CHRONIC KIDNEY DISEASE PROGRESSION IN PATIENTS WITH DIABETES WITH CURRENT AND EMERGING THERAPIES

Afternoon Session

Unmet Needs in Patients with CKD and T2D: Strategies to Manage the Disease Risk
Christoph Wanner

Mechanisms of Kidney Disease Progression: Understanding the Role of Inflammation and Fibrosis
Peter Rossing

New Approaches to Mineralocorticoid Receptor Antagonism in Management of CKD in T2D
Rajiv Agarwal

Organised by: Bayer AG
MONDAY, 16 SEPTEMBER 2019

SCIENCE TO PATIENTS:
CARDIO-RENAL-METABOLIC CONTINUUM

Afternoon Session

Chair: Jiten Vora (UK)

15:00 – 15:10 Welcome
Elisabeth Björk (Sweden)
Jiten Vora (UK)

15:10 – 15:30 Novel anti-diabetes therapies and unmet medical needs
John Buse (USA)

15:30 – 16:00 Metabolic effects of SGLT2i beyond glucosuria
Gary Lopaschuk (Canada)

16:00 – 16:30 Protective cardiovascular effects of SGLT2 inhibitors – how?
Subodh Verma (Canada)

16:30 – 17:00 Broad renal beneficial effects of SGLT2 inhibitors
Volker Vallon (USA)

17:00 – 17:25 Panel discussion
Chair: Jiten Vora (UK)

17:25 – 17:30 Closing remarks
Jiten Vora (UK)
Regina Fritsche-Danielson (Sweden)

Organised by: AstraZeneca
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>Coffee break and refreshments</td>
<td></td>
</tr>
</tbody>
</table>
| 16:00 | Welcome and Introduction  
Kamlesh Khunti                                                           |                                                                           |
| 16:05 | Mechanisms Matter: Using the Data to Differentiate Among Long-Acting GLP-1 RAs in Type 2 Diabetes  
Melanie J. Davies |                                                                           |
| 16:17 | Panel Discussion                                                                                           |                                                                           |
| 16:27 | Goals Matter: Evaluating the Evidence for Glycaemic Control and Other Targets    
Kamlesh Khunti |                                                                           |
| 16:39 | Panel Discussion                                                                                           |                                                                           |
| 16:49 | Patients Matter: Setting a Course for Success  
Francesc Xavier Cos |                                                                           |
| 17:15 | “Ask the Faculty” and Take-Home Messages    
Entire Panel |                                                                           |

Organised by:  PeerVoice (This activity is supported by an unrestricted educational grant from Novo Nordisk A/S)
Influenza is a highly contagious respiratory illness. Anyone can get influenza, but some people have a much higher risk of getting very ill from the infection. People with diabetes are 3-6 times more likely to be hospitalized during influenza epidemics. They also have a much higher rate of death associated with an influenza infection. Moreover, studies have shown that influenza can make diabetes difficult to manage. This is why yearly influenza vaccination is recommended by the World Health Organization for high-risk patients, including those with diabetes.
VERIFY:
WHAT CHANGE ARE YOU BRINGING TO OVERCOME
CLINICAL INERTIA?

Evening Session

Chair: Mark Cooper (Australia)

18:45 – 19:00 The pathophysiology of Diabetes Progression
Mark Cooper (Australia)

19:00 – 19:15 Benefits of early glycaemic control
Kamlesh Khunti (UK)

19:15 – 19:30 Why VERIFY? Clinical Evidence need
Michael Stumvoll (Germany)

19:30 – 19:35 Why VERIFY? Patient unmet needs
Patient video

19:35 – 19:45 How VERIFY is verifying early treatment intensification in diverse populations
Juliana Chan (Hong Kong)

19:45 – 19:55 How VERIFY is verifying early treatment intensification in specific populations
Paola Fioretto (Italy)

19:55 – 20:00 How VERIFY is verifying early treatment intensification in changing patient life
Patient video

20:00 – 20:10 Panel & Q&A session
All

20:10 – 20:15 Closing remarks
Mark Cooper (Australia)

Organised by: Novartis Pharma AG
IMPROVING CV RISK IN PATIENTS WITH OBESITY

Evening Session

Chair: Lars Rydén (Sweden)

18:45 – 18:50 Welcome and introduction
Lars Rydén (Sweden)

18:50 – 19:15 Does weight loss affect CV risk?
John Wilding (UK)

19:15 – 19:35 What do we know from CVOTs in obesity?
Ben Scirica (USA)

19:35 – 19:55 The major threat of our time:
the global interrelation between obesity, T2D and CVD
Lars Rydén (Sweden)

19:55 – 20:15 Panel discussion and meeting close
All

Organised by: Novo Nordisk
Evening Session

Chair: Luis Masana (Spain)

Welcome and Introduction
Luis Masana (Spain)

Urgency in treating dyslipidemia in individuals with diabetes and high CV risk
Helen Colhoun (UK)

Individuals with diabetes and high CV risk who may benefit the most from PCSK9 inhibition in your clinical practice
Luis Masana (Spain)

Evaluating the benefit/risk and safety profile of PCSK9 inhibitors: Clinical and economic implications
Ann Marie Navar (USA)

Question and answer / panel discussion
All panellists

Conclusion and key take-away messages
Luis Masana (Spain)

Organised by: SANOFI
Evening Session

Chair: Luca De Nicola (Italy)

18:45 – 18:50 Welcome and objectives
Luca De Nicola (Italy)

18:50 – 19:10 The kidney as a window to the heart
Ralph DeFronzo (USA)

19:10 – 19:30 The interlinking of cardiovascular and renal disease in type 2 diabetes
Per-Henrik Groop (Finland)

19:30 – 19:50 The role of the SGLT2 inhibitors in changing cardiovascular and renal outcomes
Vlado Perkovic (Australia)

19:50 – 20:10 Interactive panel discussion
Luca De Nicola (Italy)
Ralph DeFronzo (USA)
Per-Henrik Groop (Finland)
Vlado Perkovic (Australia)
Francisco Javier Ampudia-Blasco (Spain)

20:10 – 20:15 Meeting close
Luca De Nicola (Italy)

Organised by: Mundipharma
SUs IN THE TREATMENT OF T2DM: 
A FRESH LOOK AND NEW INSIGHTS

Evening Session

Chairs: L. Leiter (Canada)
A. Al Zaid (Saudi Arabia)

18:45 – 18:50 Introduction
A. Al Zaid (Saudi Arabia)

18:50 – 19:10 The place of SUs in guidelines: 
Why are there differences?
A. Amod (South Africa)

19:10 – 19:30 Latest evidence on SUs: what’s new in 2019?
L. Leiter (Canada)

19:30 – 19:50 The place of SUs in the evolving landscape of combination therapy
M. Yu (China)

19:50 – 20:10 Panel discussion

20:10 – 20:15 Conclusion
L. Leiter (Canada)

Organised by: SERVIER
WEDNESDAY, 18 SEPTEMBER 2019 18:45 – 20:15
SOLS HALL

GETTING TO GLYCEMIC GOALS WITH WEIGHT LOSS AND LOW RISK OF HYPOGLYCEMIA IN TYPE 2 DIABETES

Evening Session

Chair: Jaime A. Davidson (USA)

18:45 – 18:55 Welcome and Introduction
Jaime A. Davidson (USA)

Pablo Aschner (Colombia)

19:15 – 19:35 Preventing the Consequences of Hypoglycemia and Weight Gain
Bartolome Burguera (USA)

19:35 – 19:55 Update on the Cardiovascular Safety Studies
Virginia Bellido Castañeda (Spain)

19:55 – 20:15 Panel Discussion / Question and Answer Session

Symposium to be presented in Spanish.

Organised by: Worldwide Initiative for Diabetes Education
TALKING POINTS IN TYPE 2 DIABETES: AN EXPERT DIALOGUE ON CARDIO-RENAL RISK

Evening Session/Mini Symposium

Chair: Jiten Vora (UK)

19:00 – 19:10 Welcome and introduction

19:10 – 19:50 Talking points in cardio-renal risk:
  • Cardio-renal implications for the endocrinologist
  • The cardiologist’s perspective
  • Insights from nephrology
  • T2D management in the cardio-renal era

Tina Vilsbøll (Denmark)
Martin Cowie (UK)
Samy Hadjadj (France)

19:50 – 20:00 Q&A
All faculty

Organised by: AstraZeneca
Evening Session/Mini Symposium

Welcome and introduction
Ian Campbell (UK)

Metformin safety and efficacy in ASCVD
John Petrie (UK)

Metformin safety and efficacy in CKD
Peter Rossing (Denmark)

Organised by: Merck KGaA
FASTING-MIMICKING DIET AS A DIETARY APPROACH AGAINST AGING AND AGING-RELATED DISORDERS

Morning Symposium

07:30 – 08:15  Biological rationale for the use of fasting-mimicking diets as an approach for preventing and potentially for treating aging associated disorders, including cancer, diabetes, CVD and dementia; available clinical data and ongoing clinical studies of fasting-mimicking diets
Alessio Nencioni (Italy)
THURSDAY, 19 SEPTEMBER 2019  18:45 – 20:15  
CARRASCO HALL

UNDERSTANDING NASH AS A METABOLIC DISEASE

Evening Session

18:45 – 18:50  Welcome and introduction  
Kenneth Cusi (USA)

18:50 – 19:05  The global burden of NASH  
Filip Knop (Denmark)

19:05 – 19:20  Connecting NASH with its metabolic risk factors: understanding the pathophysiology  
Michael Roden (Germany)

19:20 – 19:40  NASH in the clinic: overcoming barriers to diagnosis for patients at risk  
Rohit Loomba (USA)

19:40 – 20:00  Managing NASH by targeting metabolic risk: current and emerging strategies  
Kenneth Cusi (USA)

20:00 – 20:15  Panel discussion and meeting close  
Kenneth Cusi (USA)  
Michael Roden (Germany)  
Rohit Loomba (USA)

Organised by:  Novo Nordisk
Evening Session

Chair: Julio Rosenstock (USA)

18:45 – 18:50  Welcome and introduction
Julio Rosenstock (USA)

Exploring new destinations for people living with type 1 diabetes

18:50 – 19:10  On the horizon: looking at glycemic control and beyond in T1D
Steven Edelman (USA)

19:10 – 19:30  Sailing across time in ranges and beyond
Richard Bergenstal (USA)

Setting course for cardio-renal effects in diabetes

19:30 – 19:45  Cardio-renal axis: does it matter?
Yehuda Handelsman (USA)

19:45 – 20:00  Steering across the seas of change
Julio Rosenstock (USA)

On the horizon

20:00 – 20:10  Discussion and Q&A
Faculty panel

20:10 – 20:15  Closing remarks
Julio Rosenstock (USA)

Organised by: Sanofi and Regeneron
FOCUS ON THE PATIENT: NEW INSIGHTS FOR CLINICIAN CHOICES IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

Evening Session

Co-Chairs: Larry Leiter (Canada)
            Alice Cheng (Canada)

18:45 – 18:45  Welcome and Opening Remarks
                Larry Leiter (Canada)
                Alice Cheng (Canada)

18:45 – 19:05  Understanding the Right Patient for the Right Clinical Treatment Considerations
                Bernie Zinman (Canada)

19:05 – 19:10  Q & A

19:10 – 19:25  Addressing Clinical Questions – The Latest Understanding from the CompoSIT Trials
                Juan Frias (USA)

19:25 – 19:30  Q & A

19:30 – 19:45  The Latest Evidence for Ertugliflozin, an SGLT2 Inhibitor for Patients with Type 2 Diabetes
                Richard Pratley (USA)

19:45 – 19:50  Q & A

19:50 – 20:10  How do we Overcome Clinical Inertia after Metformin – An Interactive Case
                Faculty

20:10 – 20:15  Final Comments and Summary
                Co-Chairs

Organised by: MSD
GETTING AT THE HEART OF COMPREHENSIVE DISEASE CONTROL IN TYPE 2 DIABETES: WHAT’S NEW?

Evening Session

**Moderator:** Melanie J. Davies

**18:45 – 18:50 Welcome and Introduction**
Melanie J. Davies

**18:50 – 19:05 Presentation 1:**
Patient-centered Management of T2DM
Melanie J. Davies

**19:05 – 19:10 Panel Discussion**
All Faculty

**19:10 – 19:25 Presentation 2:**
Preventing Cardiovascular Complications in Patients with Type 2 Diabetes
Juris Meier

**19:25 – 19:30 Panel Discussion**
All Faculty

**19:30 – 19:40 Presentation 3:**
Preventing Renal Complications in Patients with Type 2 Diabetes
Janaka Karaliedde

**19:40 – 19:45 Panel Discussion**
All Faculty

**19:45 – 20:05 Presentation 4:**
Comprehensive Management of Type 2 Diabetes
All Faculty

**20:05 – 20:15 Conclusions and Q&A**
Melanie J. Davies
All Faculty

**Organised by:** Eli Lilly and Company
Evening Session

Welcome and Introduction

Development History – Initial Idea to Key Milestones in SugarBeat®'s Development

SugarBeat® Technology – Overview and how it differs from invasive CGM technologies (electrochemical and fluorescence), MARD, calibration, Glucose Trending®

Clinical Use
a) T2 Oral
b) Insulin Treated Patients
c) Diagnosing Pre-Diabetics
d) Therapy Optimisation & Intensification
e) Weight & Nutrition Management

Patient User-Experience
a) T2 Oral
b) T2 Insulin

Questions & Answers

Closing

Organised by: Nemaura Medical
TYPE 2 DIABETES, HYPOGONADISM 
AND TESTOSTERONE THERAPY

Evening Session/Mini Symposium

Chairs: Lars Rydén (Sweden) 
Markolf Hanefeld (Germany)

19:00 – 19:05 Opening remarks 
Markolf Hanefeld (Germany)

19:05 – 19:30 Beneficial effects of Testosterone Therapy on Obesity, 
CV Risk and Mortality in Type 2 Diabetes 
Hugh Jones (UK)

19:30 – 19:55 Testosterone Therapy for Treatment of Type 2 Diabetes 
Sandeep Dhindsa (USA)

19:55 – 20:00 Closing remarks 
Lars Rydén (Sweden)

Organised by: Bayer AG
INDUSTRY “MEET-THE-EXPERT”-SESSIONS

TUESDAY, 17 SEPTEMBER 2019  10:30 – 11:00
NETWORKING HUB

EXPANDING KNOWLEDGE ON GLP-1RAS IN CARDIOMETABOLIC CARE

Morning Session

10.30 – 10.40  Analysing the current role of GLP-1RAs’ cardiovascular effects: an endocrinologist’s perspective
Filip Knop (Denmark)

10.40 – 10.50  Exploring the future role of GLP-1RAs’ cardiovascular effects: a cardiologist’s perspective
Subodh Verma (Canada)

10.50 – 11.00  Discussion/Q&A
Subodh Verma and Filip Knop

Organised by: Novo Nordisk

TUESDAY, 17 SEPTEMBER 2019  11:30 – 12:00
NETWORKING HUB

NON-ALCOHOLIC STEATOHEPATITIS (NASH): METABOLIC DISEASE OF THE LIVER

Morning Session

11.30 – 12.00  Non-alcoholic steatohepatitis (NASH): Metabolic disease of the liver
Philip Newsome (UK)

Organised by: Novo Nordisk
INDUSTRY “MEET-THE-EXPERT”-SESSIONS

TUESDAY, 17 SEPTEMBER 2019 13:00 – 13:30
NETWORKING HUB

ADDRESSING COMMON CLINICAL CHALLENGES – NEW DATA FROM THE ERTUGLIFLOZIN VERTIS PROGRAM FOR PATIENTS WITH TYPE 2 DIABETES

Lunch Session
Speaker: Sam Dagogo Jack (USA)
Organised by: MSD

TUESDAY, 17 SEPTEMBER 2019 14:00 – 14:30
NETWORKING HUB

Hb A1c: ANALYTICAL ACCURACY AND CHALLENGES IN CLINICAL INTERPRETATION

Lunch Session
Speaker: David B. Sacks (USA)
Organised by: Sebia

WEDNESDAY, 18 SEPTEMBER 2019 10:30 – 11:00
NETWORKING HUB

THE PLACE OF AUTOMATED INSULIN DELIVERY SYSTEMS IN THE T1D PATIENT TREATMENT TODAY

Morning Session
Chairs: Sylvia Franc (France), Guillaume Charpentier (France)

State of the Art of Artificial Pancreas, 2019
Roman Hovorka (UK)

DBLG1 System by Diabeloop: Current clinical evidence & nextcoming studies
Pierre-Yves Benhamou (France)

How technologically advanced mono-hormonal system can do better than bi-hormonal artificial pancreas device?
Erik Huneker (France)

Organised by: Diabeloop
INDUSTRY “MEET-THE-EXPERT”-SESSIONS

WEDNESDAY, 18 SEPTEMBER 2019 11:30 – 12:00
NETWORKING HUB

PICTURING THE LIPODYSTROPHY PATIENT – FROM SIGNS AND SYMPTOMS TO DIAGNOSIS AND MANAGEMENT

Morning Session
Speaker: Alessandra Gambineri (Italy)
Organised by: Aegerion

WEDNESDAY, 18 SEPTEMBER 2019 13:00 – 13:30
NETWORKING HUB

EXPLORING NEW DESTINATIONS FOR PEOPLE LIVING WITH TYPE 1 DIABETES

Lunch Session
Speaker: Thomas Danne (Germany)
13:00 – 13:05 Welcome and introduction
13:05 – 13:25 Striving for balance: adjunctive therapies for people living with T1D
13:25 – 13:30 Q&A and closing remarks
Organised by: SANOFI

WEDNESDAY, 18 SEPTEMBER 2019 14:00 – 14:30
NETWORKING HUB

FURTHER INSIGHTS FROM THE BRIGHT TRIAL: EVALUATION OF GLYCEMIC OUTCOMES IN PATIENTS WITH RENAL IMPAIRMENT

Lunch Session
Speaker: Alice Cheng
Organised by: SANOFI
INDUSTRY “MEET-THE-EXPERT”-SESSIONS

THURSDAY, 19 SEPTEMBER 2019
10:30 – 11:00
NETWORKING HUB

EXPLORING THE EARLY COMPLICATIONS OF T2D:
WHAT HAVE THE SGLT2 INHIBITORS TAUGHT US?

Morning Session

Cardio-renal complications of T2D
Kåre Birkeland (Norway)

The case for early intervention with SGLT2 inhibitors
Mikhail Kosiborod (USA)

Q&A session
All faculty

Organised by: Aegerion

THURSDAY, 19 SEPTEMBER 2019
13:00 – 13:30
NETWORKING HUB

SNAPSHOTS FROM PATIENT CASES IN PARTIAL LIPODYSTROPHY

Lunch Session

Speaker: Camille Vatier (France)

Organised by: Aegerion

THURSDAY, 19 SEPTEMBER 2019
14:00 – 14:30
NETWORKING HUB

GETTING TO GOAL: TREATMENT OPTIONS FOR ADULT
PATIENTS WITH T2D AND HIGH HbA1c

Lunch Session

Speaker: Helmut Brath (Austria)

Organised by: SANOFI
INDUSTRY “MEET-THE-EXPERT”-SESSIONS

THURSDAY, 19 SEPTEMBER 2019 15:00 – 15:30
NETWORKING HUB

TYPE 2 DIABETES? THINK LIVER
EXPLORING NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN YOUR DIABETES CLINIC

Afternoon Session
Speakers: Kenneth Cusi, Salvador Augustin

Organised by: Gilead Sciences, Inc.
<table>
<thead>
<tr>
<th>Company</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.Menarini Diagnostics srl</td>
<td>G.02</td>
</tr>
<tr>
<td>Abbott</td>
<td>B.03, B.04</td>
</tr>
<tr>
<td>Accelerating Medicines Partnership – T2D Federation Team</td>
<td>M.07</td>
</tr>
<tr>
<td>ACON Laboratories, Inc.</td>
<td>A.12</td>
</tr>
<tr>
<td>ADELPHI REAL WORLD</td>
<td>M.06</td>
</tr>
<tr>
<td>Aegerion</td>
<td>K.01</td>
</tr>
<tr>
<td>aiScreenings</td>
<td>IZ.02</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>B.07</td>
</tr>
<tr>
<td>Bayer AG</td>
<td>B.01</td>
</tr>
<tr>
<td>Bionime GmbH</td>
<td>G.05</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>F.01</td>
</tr>
<tr>
<td>Capenergy Medical</td>
<td>A.21</td>
</tr>
<tr>
<td>CODHy</td>
<td>A.19</td>
</tr>
<tr>
<td>Dexcom</td>
<td>D.05</td>
</tr>
<tr>
<td>Diabeloop</td>
<td>IZ.01</td>
</tr>
<tr>
<td>Diabetes Knowledge in Practice</td>
<td>A.08</td>
</tr>
<tr>
<td>DIABNEXT</td>
<td>A.14</td>
</tr>
<tr>
<td>DiagnOptics Technologies BV</td>
<td>G.03</td>
</tr>
<tr>
<td>Diamesco Co. Ltd.</td>
<td>H.07</td>
</tr>
<tr>
<td>DxGen Corp</td>
<td>A.06</td>
</tr>
<tr>
<td>ECHOSENS</td>
<td>B.06</td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td>F.02</td>
</tr>
<tr>
<td>ELSEVIER</td>
<td>A.17</td>
</tr>
<tr>
<td>EOFlow Co., Ltd.</td>
<td>C.04</td>
</tr>
<tr>
<td>Eyenuk, Inc.</td>
<td>D.02</td>
</tr>
<tr>
<td>Feel Tech Bio</td>
<td>K.05</td>
</tr>
<tr>
<td>ForaCare Suisse AG</td>
<td>H.03</td>
</tr>
<tr>
<td>Frontiers</td>
<td>A.18</td>
</tr>
<tr>
<td>GENFIT</td>
<td>H.08</td>
</tr>
<tr>
<td>Gilead Sciences, Inc.</td>
<td>G.06</td>
</tr>
<tr>
<td>Glenmark Pharmaceuticals Ltd</td>
<td>C.05</td>
</tr>
<tr>
<td>Glooko</td>
<td>B.09</td>
</tr>
<tr>
<td>Gubra</td>
<td>M.04</td>
</tr>
<tr>
<td>IMPETO MEDICAL</td>
<td>A.13</td>
</tr>
<tr>
<td>Infinovo Medical Co., Ltd</td>
<td>B.05</td>
</tr>
<tr>
<td>Insulet Ltd</td>
<td>B.02</td>
</tr>
<tr>
<td>i-SENS, Inc.</td>
<td>B.08</td>
</tr>
<tr>
<td>Jana Care</td>
<td>IZ.07</td>
</tr>
<tr>
<td>L. MOLTENI &amp; C. dei Fili Alitti S.p.A.</td>
<td>H.05</td>
</tr>
<tr>
<td>LenoMed Corporation</td>
<td>H.06</td>
</tr>
<tr>
<td>LifeScan</td>
<td>E.03</td>
</tr>
<tr>
<td>L-Nutra Italia S.r.l.</td>
<td>M.02</td>
</tr>
<tr>
<td>LumiraDx</td>
<td>H.04</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUPIN LTD</td>
<td>D.04</td>
</tr>
<tr>
<td>MED TRUST Handelsges.m.b.H.</td>
<td>A.09</td>
</tr>
<tr>
<td>Medisensor</td>
<td>G.07</td>
</tr>
<tr>
<td>Medscape Diabetes &amp; Endocrinology</td>
<td>E.04</td>
</tr>
<tr>
<td>Medtronic</td>
<td>K.02</td>
</tr>
<tr>
<td>Medtrum Technologies Inc.</td>
<td>H.02</td>
</tr>
<tr>
<td>Metabolic Endocrine Education Foundation</td>
<td>A.03</td>
</tr>
<tr>
<td>MicroTech Medical (hangzhou)Co.,Ltd</td>
<td>D.03</td>
</tr>
<tr>
<td>MSD</td>
<td>D.01</td>
</tr>
<tr>
<td>Mundipharma</td>
<td>G.01</td>
</tr>
<tr>
<td>Novartis Pharma AG</td>
<td>D.07</td>
</tr>
<tr>
<td>Novo Nordisk</td>
<td>C.02, F.03</td>
</tr>
<tr>
<td>Nucleues Dynamics</td>
<td>IZ.03</td>
</tr>
<tr>
<td>Owen Mumford Ltd</td>
<td>G.04</td>
</tr>
<tr>
<td>PATIA</td>
<td>IZ.06</td>
</tr>
<tr>
<td>PIKDARE</td>
<td>K.09</td>
</tr>
<tr>
<td>ProSciento, Inc.</td>
<td>C.03</td>
</tr>
<tr>
<td>quin, supported by Diabetes Center Berne</td>
<td>IZ.05</td>
</tr>
<tr>
<td>Remidio Innovative Solutions</td>
<td>IZ.04</td>
</tr>
<tr>
<td>Research Diets, Inc.</td>
<td>A.01</td>
</tr>
<tr>
<td>Roche Diabetes Care GmbH</td>
<td>D.06</td>
</tr>
<tr>
<td>SANOFI</td>
<td>C.01</td>
</tr>
<tr>
<td>Sebia</td>
<td>B.02A</td>
</tr>
<tr>
<td>SERVIER</td>
<td>E.01</td>
</tr>
<tr>
<td>Shandong Lianfa Medical</td>
<td>A.20</td>
</tr>
<tr>
<td>Plastic Products Co., Ltd.</td>
<td>A.20</td>
</tr>
<tr>
<td>SOOIL Development Co., Ltd</td>
<td>K.04</td>
</tr>
<tr>
<td>Springer Healthcare</td>
<td>A.04</td>
</tr>
<tr>
<td>Tandem Diabetes Care</td>
<td>D.08</td>
</tr>
<tr>
<td>Terumo Corporation</td>
<td>K.10</td>
</tr>
<tr>
<td>Undermyfork</td>
<td>IZ.08</td>
</tr>
<tr>
<td>University of Leicester/ Leicester Diabetes Centre</td>
<td>A.08A</td>
</tr>
<tr>
<td>ViCentra</td>
<td>H.10</td>
</tr>
<tr>
<td>VibroSense Dynamics</td>
<td>A.07</td>
</tr>
<tr>
<td>Vitrex Medical A/S</td>
<td>K.06</td>
</tr>
<tr>
<td>WeHealth Digital Medicine</td>
<td>E.02</td>
</tr>
<tr>
<td>Wisepress</td>
<td>A.15</td>
</tr>
<tr>
<td>Worldwide Initiative for Diabetes Education</td>
<td>A.02</td>
</tr>
<tr>
<td>Wuxi BioHermes Biomedical Technology Co., Ltd.</td>
<td>A.11</td>
</tr>
<tr>
<td>Ypsomed AG</td>
<td>H.01</td>
</tr>
<tr>
<td>Zhejiang POCTech Co., Ltd</td>
<td>A.16</td>
</tr>
</tbody>
</table>

Status September 2019, details are subject to change.